Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

Aptose Biosciences Inc TSX: APS-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

More stories below advertisement

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

GlobeNewswire - Tue Jun 1, 4:43PM CDT

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 1, 2021 (the "Meeting"). A total of 72.83% of the issued and outstanding common shares of the Company were represented by shareholders present or represented by proxy at the Meeting.

The Company is pleased to announce that all of the nominees listed in the proxy statement dated April 20, 2021 were elected as Directors. The results of the vote are detailed below:

Nominee               Votes For  % Votes Votes      % Votes
                                 For     Withheld   Withheld
Ms. Carol G. Ashe     41,927,965 99.25   317,922    0.75
Dr. Denis Burger      40,351,406 95.52   1,894,481  4.48
Ms. Caroline M. Loewy 31,606,672 74.82   10,639,215 25.18
Dr. Erich Platzer     40,337,583 95.48   1,908,304  4.52
Dr. William G. Rice   41,767,537 98.87   478,350    1.13
Dr. Mark D. Vincent   40,365,017 95.55   1,880,870  4.45
Mr. Warren Whitehead  40,468,725 95.79   1,777,162  4.21

Aptose shareholders also voted in favor of the following matters:

Please refer to the Company's management proxy circular available on SEDAR at www.sedar.com or EDGAR https://www.sec.gov/edgar.shtml for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR and EDGAR.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies. The first investigational product, luxeptinib, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML). The second investigational product, APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high-risk myelodysplastic syndrome (MDS).

For further information, please contact:

Aptose Biosciences Inc. LifeSci Advisors, LLC
Susan Pietropaolo       Dan Ferry, Managing Director
Investor Relations      617-535-7746
201-923-2049            Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com

https://ml.globenewswire.com/media/3f4ab307-5947-4ef1-b5b5-c2c66933728a/small/aptose-biosciences-inc-logo.jpg

https://ml.globenewswire.com/media/3f4ab307-5947-4ef1-b5b5-c2c66933728a/small/aptose-biosciences-inc-logo.jpg

comtex tracking

COMTEX_387681402/2010/2021-06-01T17:43:53

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies